Die behandeling van VIGS - Geneesmiddels en vaksiene - Wat hou die toekoms in?


The developing epidemic of acquired immunodeficiency syndrome (AIDS) has prompted a broadly based research effort to find drugs and vaccines for preventing and treating this disease. Compounds such as zidovudine (AZT), ampligen and the broad spectrum of pyrimidine dideaxynucleosides have yielded some promise for the treatment of AIDS in terms of better quality of life for sufferers, but no cure is in sight yet. Also the quest for therapeutic and preventative vaccines has also been ongoing for several years. The latest development of the Salk vaccine has led to wild speculation in the lay press of a cure for AIDS. However, some seemingly insurmountable practical and moral-ethical problems beset both the development of AIDS chemotherapy and an AIDS vaccine. The most vexing of these problems is the lack of a suitable animal model for testing and the consequent questions of whether uninfected or HIV-infected but symptom-free volunteers can or should be used in testing potentially lethal compounds or vaccines.

Copyright information

  • Ownership of copyright in terms of the Work remains with the authors.
  • The authors retain the non-exclusive right to do anything they wish with the Work, provided attribution is given to the place and detail of original publication, as set out in the official citation of the Work published in the journal. The retained right specifically includes the right to post the Work on the authors’ or their institutions’ websites or institutional repository.

Publication and user license

  • The authors grant the title owner and the publisher an irrevocable license and first right and perpetual subsequent right to (a) publish, reproduce, distribute, display and store the Work in  any form/medium, (b) to translate the Work into other languages, create adaptations, summaries or extracts of the Work or other derivative works based on the Work and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts and derivative works, (c) to license others to do any or all of the above, and (d) to register the Digital Object Identifier (DOI) for the Definitive Work.
  • The authors acknowledge and accept the user licence under which the Work will  be published as set out in https://creativecommons.org/licenses/by/4.0/ (Creative Commons Attribution License South Africa)
  • The undersigned warrant that they have the authority to license these publication rights and that no portion of the copyright to the Work has been assigned or licensed previously to any other party.

Disclaimer: The publisher, editors and title owner accept no responsibility for any statement made or opinion expressed by any other person in this Work. Consequently, they will not be liable for any loss or damage sustained by any reader as a result of his or her action upon any statement or opinion in this Work. 
In cases where a manuscript is NOT accepted for publication by the editorial board, the portions of this agreement regarding the publishing licensing shall be null and void and the authors will be free to submit this manuscript to any other publication for first publication.

Our copyright policies are author-friendly and protect the rights of our authors and publishing partners.